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OBJECTIVES: Although several studies have investigated the effects of diabetes on hearing loss, the relationship
between these two conditions remains unclear. Some studies have suggested that diabetes may cause senso-
rineural hearing loss, whereas others have failed to find an association. The biggest challenge in investigating
the association between diabetes and hearing loss is the presence of confounding variables and the complexity
of the auditory system. Our study investigated the association between diabetes and sensorineural hearing loss.
We evaluated the influence of time from diabetes diagnosis on this association after controlling for age, gender,
and hypertension diagnosis and excluding those subjects with exposure to noise.
METHODS: This cross-sectional study evaluated 901 adult and elderly Brazilian Longitudinal Study of Adult
Health (ELSA-Brasil) participants from Sa˜o Paulo, Brazil who underwent audiometry testing as part of
ELSA-Brasil’s baseline assessment.
RESULTS: Hearing thresholds and speech test results were significantly worse in the group with diabetes than in the
group without diabetes. However, no significant differences were found between participants with and without
diabetes after adjusting for age, gender, and the presence of hypertension. Hearing thresholds were not affected
by occupational noise exposure in the groups with and without diabetes. In addition, no association between the
duration of diabetes and hearing thresholds was observed after adjusting for age, gender, and hypertension.
CONCLUSION: We found no association between the duration of diabetes and worse hearing thresholds after
models were adjusted for age, gender, and the presence of hypertension.
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’ INTRODUCTION
The burden of diabetes is increasing worldwide (1), includ-
ing in Brazil (2–4). In 1986, a national survey reported a pre-
valence of diabetes for people aged 30–69 years of 7.6% (2),
and by 2000, the prevalence had increased to 12.1% (3). Most
recently, the elderly Brazilian Longitudinal Study of Adult
Health (ELSA-Brasil) found a frequency of diabetes mellitus
of 19.8% for adults aged 35–74 years (4).
In addition to the cardiovascular outcomes and the long-
term damage to the kidneys, eyes, and nervous system caused
by diabetes (5), this disease was also associated with altera-
tions in hearing function in a meta-analysis of 18 clinical and
epidemiological studies (6).
The pathological support to this association may be related
to an increase in capillary lesions in the cochlea, more speci-
fically in the stria vascularis and basilar membrane. Other
studies have also reported a reduction in the number of
spiral ganglion neurons. These differences could be related to
the duration of diabetes and to comorbidities that could
affect the inner ear (7).
Although several studies have investigated the effects of
diabetes on hearing loss (HL), the relationship between these
two conditions remains unclear. Some studies have suggested
that diabetes may cause sensorineural hearing loss (SNHL)
(6,8–10), whereas others have failed to find an association
(11–15). The biggest difficulty in investigating the association
between diabetes and HL is the presence of confounding
variables and the complexity of the auditory system (16,17).DOI: 10.6061/clinics/2017(01)02
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In this study, we investigated the association between dia-
betes and SNHL. We evaluated the influence of other factors
such as age, gender, exposure to noise, hypertension diag-
nosis, and duration of diabetes on this association.
’ MATERIALS AND METHODS
This study was approved by the Ethics Committee of the
University Hospital at University of São Paulo (n 883/09).
Study design
In this ancillary cross-sectional study, we evaluated
901 ELSA-Brasil participants from São Paulo (total ELSA-
Brasil participants in São Paulo, 5,061) who were invited to
participate in the study and agreed to undergo audiometry
testing as part of ELSA-Brasil’s baseline assessment. Infor-
med consent was given by all participants. The study was
approved by the Ethics Committee of the University Hospi-
tal at University of São Paulo (n 883/09).
The design, objectives, and cohort profile of ELSA-Brasil
have been published in detail elsewhere (18,19). The
ELSA-Brasil is a prospective cohort study of 15,105 civil
servants from six institutions in different Brazilian cities (São
Paulo, Belo Horizonte, Porto Alegre, Salvador, Rio de Janeiro,
and Vitória). All active or retired employees aged 35–74 years
were eligible for the study. The baseline assessment consisted
of a 7-hour examination, which took place from August 2008
to December 2010. Blood samples were taken after an over-
night fast, and an oral 75 g glucose tolerance test and gly-
cated hemoglobin measurements were performed (20).
Hearing examination
After otological inspection, an audiological assessment was
conducted. Screening acoustic immittance measurements
(Madsen Otoflex 100) were performed to exclude middle
ear disorders.
Pure-tone audiometry was performed using air conduction
at octave frequencies from 250-8,000 Hz and bone conduc-
tion at 500-4,000 Hz.
Speech tests included the Speech Reception Threshold (SRT)
and the Speech Discrimination Score (SDS). The SRT assesses
people’s ability to hear and understand standardized three-
syllable words (threshold in decibel hearing level (dBHL)),
and the SDS evaluates people’s ability to hear and under-
stand standardized one-syllable words (percentage of words
correctly identified).
All tests were performed using a Madsen Itera II audio-
meter in a sound-proof room.
Study variables
Socio-demographic characteristics and medical and occu-
pational histories were obtained. Diabetes was defined as
follows: medical history of diabetes; reported use of medi-
cations to treat diabetes; fasting serum glucose X7 mmol/l;
glycated hemoglobin (HbA1c) level X48 mmol/mol; or 2-h
oral glucose tolerance test with 75 g of glucoseX11.1 mmol/l.
Hypertension was defined as follows: reported use of medica-
tions to treat hypertension; systolic blood pressureX140 mmHg;
or diastolic blood pressure X90 mmHg. Dyslipidemia was
defined as follows: reported use of lipid-lowering treatment or
low-density lipoprotein (LDL) cholesterol levelX3.36 mmol/l.
Audiometric and speech test variables were compared
between left and right ears in each group (D: group with
diabetes and ND: group without diabetes). No significant
differences were found between the left and right ears,
they were grouped. Then, we calculated the mean values
(both ears together) for the following measures: each audio-
metric frequency (threshold by frequency); low- to middle-
range frequencies (250–2,000 Hz); high-range frequencies
(3000–8,000 Hz); SRT and SDS. For each audiometric freq-
uency mean, a value 425 dBHL was considered HL (21).
Statistical analysis
Continuous variables were expressed as means± SD, and
categorical variables were expressed as proportions. The chi-
square and Kruskal-Wallis tests and one-way analysis of variance
(ANOVA) were used whenever applicable. We constructed
linear regression models using the hearing threshold values,
SRT, and SDS for each frequency as dependent variables to
evaluate their association with diabetes. The following models
were constructed: (1) crude, (2) adjusted for age; and (3)
adjusted for age, gender, and hypertension diagnosis. We also
built binary logistic regression models to study the association
between hearing impairment in each frequency range (low-
middle or high) and diabetes diagnosis. The odds ratio (OR)
was calculated considering the number of individuals with
hearing impairment in each frequency range (low-middle or
high) in the D and ND groups.
We constructed similar models including only individuals
with diabetes (N=191) to determine if the time from diabetes
diagnosis was associated with HL. In this analysis, we set
cutoff times at 1, 5, 7, and 9 years from diagnosis. We also
performed a sensitivity analysis excluding individuals with a
history of noise exposure. All analyses were performed using
R software v.3.1.2. The significance level was set at 0.05.
’ RESULTS
Of the 901 participants, 191 (21.2%) had diabetes. Among
those with diabetes, HbA1c levels were available for
190 participants (99.5%), and adequate glycemic control
(o53 mmol/mol) was found in 149 (78.4%) participants.
Table 1 shows the baseline characteristics for the ELSA-Brasil
study population. The mean time from diagnosis was 4.0±5.13
years, and the age at diagnosis ranged from 30 to 72 years
(50.47±9.57 yrs).
Table 1 shows that participants in the D group were older
and included more men and more participants with hyper-
tension compared to the ND group. In addition, glucose,
HbA1c, systolic and diastolic blood pressure, triglycerides,
and creatinine levels were significantly higher in the D than
the ND group. Results for audiometry testing at 250–8,000 Hz,
SRT, and SDS were significantly worse in participants in the D
than ND group.
Table 2 shows the number of participants with HL in each
frequency range (low-middle and high). The number of
participants with HL was significantly higher in the D group
than the ND group. The OR for both frequency ranges showed
a difference between the groups (crude model). However, in the
adjusted model, this difference between groups was lost.
We also analyzed the audiometric measurements using
linear models. Table 3 shows the beta coefficients for the asso-
ciation between audiometric measurements and a diagnosis
of diabetes. In this analysis (crude model), all audiometric
measurements and speech test variables were significantly
worse in the D group than the ND group. However, the dif-
ferences between groups were not significant when the models
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were adjusted for age. This lack of significance remained after
further adjustment for gender and hypertension diagnosis.
We also performed a subgroup analysis of participants
with diabetes to evaluate the association between hear-
ing loss and time from diabetes diagnosis. Among the 191
participants, 3 (1.6%) could not precisely time their diabetes
diagnosis and were excluded from these analyses. Among
the remaining 188 individuals, 98 (52.1%) did not report
themselves as diabetic and were diagnosed based on the
results of the ELSA-Brasil laboratory baseline assessment.
Therefore, these subjects were considered as having a time
from diabetes diagnosis of zero. Participants in the D group
were grouped according to the time from diagnosis (o9
years orX9 years). Although the mean hearing threshold for
Table 1 - Baseline characteristics of study participants.
Without diabetes (ND) N = 710 With diabetes (D) N = 191 p
Age (years) (Mean ± SD) 51.2 ± 8.9 57.4 ± 9.0 o0.001
Women sex (%) 389 (54.8) 87 (45.5) 0.029
Glucose (mmol/l) 5.76 ± 0.47 7.97 ± 2.76 o0.001
HbA1c (%) (mmol/mol) 5.3 ± 0.6 (34 ± 6.6) 6.5 ± 1.3 (48 ± 14.3) o0.001
Hypertension (%) 185 (26.1) 112 (58.9) o0.001
Systolic BP (mmHg)(Mean ± SD) 118.4 ± 14.9 128.1 ± 19.3 o0.001
Diastolic BP (mmHg)(Mean ± SD) 74.8 ± 10.1 79.4 ± 11.1 o0.001
Dyslipidemia (%) 391 (55.1) 118 (61.8) 0.115
Total cholesterol (mmol/l) (Mean ± SD) 5.48 ± 0.98 5.41 ± 1.09 0.221
LDL cholesterol (mmol/l) (Mean ± SD) 3.38 ± 0.84 3.30 ± 0.96 0.107
HDL cholesterol (mmol/l) (Mean ± SD) 1.45 ± 0.35 1.31 ± 0.29 o0.001
Triglycerides (mmol/l) (Mean ± SD) 1.47 ± 1.03 1.82 ± 1.15 o0.001
Creatinine (mg/dl) (Mean ± SD) 0.93 ± 0.22 0.99 ± 0.24 0.001
250 Hz (dBHL)(Mean ± SD) 12.6 ± 7.8 14.6 ± 8.9 0.002
500 Hz (dBHL)(Mean ± SD) 11.5 ± 8.1 13.9 ± 9.1 o0.001
1000 Hz(dBHL)(Mean ± SD) 11.6 ± 9.0 13.8 ± 10.1 o0.001
2000 Hz(dBHL)(Mean ± SD) 12.6 ± 11.1 16.2 ± 12.2 o0.001
3000 Hz(dBHL)(Mean ± SD) 15.3 ± 13.5 20.3 ± 14.9 o0.001
4000 Hz(dBHL)(Mean ± SD) 18.8 ± 15.5 25.1 ± 16.8 o0.001
6000 Hz(dBHL)(Mean ± SD) 25.1 ± 17.4 32.2 ± 18.2 o0.001
8000 Hz(dBHL)(Mean ± SD) 24.1 ± 19.6 31.7 ± 20.6 o0.001
SRT (dBHL)(Mean ± SD) 13.6 ± 8.0 16.2 ± 9.1 o0.001
SDS (%) (Mean ± SD) 96.2 ± 4.8 94.9 ± 6.3 0.001
SD = standard deviation; BP = blood pressure
Table 2 - Individuals (n) with hearing impairment in each range frequencies (low-middle or high) for both groups (N and ND),
odds-ratio and p-value in crude and adjusted model.
Low-middle range frequencies.
n (%) hearing impairment
High range frequencies.
n (%) hearing impairment
Without diabetes
(ND) N = 710
40 (5.6%) 187 (26.3%)
With diabetes
(D) N = 191
20 (10.5%) 88 (46.3%)
Crude model
(OR; 95% CI)
1.96 (1.12 – 3.44) 2.39 (1.72 – 3.32)
p-value 0.019 o0.001
Adjusted model
(OR; 95% CI)
1.03 (0.56 – 1.92) 1.18 (0.78 – 1.78)
p-value 0.915 0.446
Adjusted model is adjusted for age, sex and hypertension diagnosis. OR: Odds ratio. 95% CI: 95% confidence interval.
Table 3 - Beta-coefficients for the association between mean audiometric measurements and diabetes mellitus in crude and adjusted
models.
Crude Adjusted for age Full adjusted
250 Hz 1.99 (0.71 to 3.27; p=0.002) 0.66 (-0.64 to 1.95; p=0.319) 0.59 (-0.73 to 1.92; p=0.378)
500 Hz 2.39 (1.06 to 3.71; po0.001) 0.84 (-0.48 to 2.17; p=0.213) 0.69 (-0.68 to 2.05; p=0.323)
1000 Hz 2.26 (0.77 to 3.74; p=0.003) 0.20 (-1.26 to 1.67; p=0.786) 0.18 (-1.33 to 1.69; p=0.815)
2000 Hz 3.63 (1.82 to 5.44; po0.001) 0.34 (-1.38 to 2.06; p=0.696) 0.22 (-1.54 to 1.98; p=0.807)
3000 Hz 5.08 (2.88 to 7.28; po0.001) 0.96 (-1.11 to 3.03; p=0.363) 0.69 (-1.38 to 2.77; p=0.513)
4000 Hz 6.23 (3.71 to 8.75; po0.001) 1.39 (-0.96 to 3.74; p=0.247) 0.93 (-1.39 to 3.25; p=0.433)
6000 Hz 7.10 (4.30to 9.91; po0.001) 1.18 (-1.38 to 3.74; p=0.366) 1.08 (-1.51 to 3.66; p=0.415)
8000 Hz 7.58 (4.41 to 10.75; po0.001) 0.07 (-2.70to 2.84; p=0.960) 0.13 (-2.68 to 2.95; p=0.926)
SRT 2.55 (1.22 to 3.87; po0.001) 0.25 (-1.01 to 1.51; p=0.701) 0.08 (-1.21 to 1.38; p=0.900)
SDS -1.28 (-2.11 to -0.45; p=0.003) -0.37 (-1.20 to 0.47; p=0.390) -0.31 (-1.16 to 0.54; p=0.476)
Full adjusted models are adjusted for age, sex and hypertension diagnosis.
7
CLINICS 2017;72(1):5-10 Diabetes and SNHL: is there an association?
Samelli AG et al.
most frequencies and the SRT were lower in participants
diagnosed X9 years than in those diagnosed o9 years,
no significant differences were found after adjusting for age,
gender, and the presence of hypertension (p-values 0.627;
0.489; 0.785; 0.611; 0.477; 0.914; 0.207; 0.277; 0.172; and 0.478,
respectively). Similarly, no significant differences in hearing
thresholds or speech tests were found between the D and ND
groups at 1, 5, or 7 years from diagnosis after adjusting for
age, gender, and presence of hypertension.
We conducted another analysis excluding the 71 participants
in the D group (37%) and 260 participants in the ND group
(36.6%) with a history of noise exposure. In both groups, the
mean hearing thresholds were not significantly different after
these participants were removed from the analysis. The p-
values for the comparison of hearing thresholds between
groups considering the whole sample or only those without a
history of noise exposure are shown in Figure 1.
’ DISCUSSION
We investigated the association between diabetes and SNHL
in ELSA-Brasil participants from the São Paulo investigation
center. In crude models, we found significant differences
between the D and ND groups in most variables evaluated,
including demographic characteristics (age and gender),
fasting blood collection and blood pressure variables. Partici-
pants in the D group were older, and there were also more
men and more hypertensive participants in the D than ND
group.
Although the LDL and total cholesterol levels were higher
in the D group, no significant differences were found between
groups. Conversely, triglyceride levels were significantly
higher in D than in ND participants. Similar findings were
reported by Kakarlapudi et al. (22), who suggested that the
similar cholesterol levels may be because persons with diabetes
are more aggressively treated with antilipemic medications
such as statins that lower LDL and total cholesterol but have a
weaker effect on triglyceride levels.
In the crude model, pure-tone audiometry thresholds and
speech test results were significantly worse in the D group
than the ND group (Table 1). These findings are in agree-
ment with studies showing that people with diabetes are at a
high risk of HL (6,8,16,22–25).
Analysis of the crude model (Table 2) supports these pre-
vious findings (6,8,16,22–25) because the number of partici-
pants with HL was significantly higher in the D than ND
group at both low- to middle-range frequencies and high-
range frequencies. However, analysis of an adjusted model
(Table 2) showed no difference between the D and ND groups
at either low- to middle-range or high-range frequencies.
A meta-analysis by Horikawa et al. (9) included data
from 13 studies (20,194 participants and 7,377 cases) that
compared the prevalence of HL between D and ND adults.
Type 1 and 2 diabetes participants (15–84 years old) with a
duration of diabetes from 4 to 410 years were included
(some studies did not provide this information). The overall
pooled OR of HL for D compared to ND participants was 2.15
(95% CI: 1.72–2.68), and the prevalence of HL was higher in D
participants than in ND participants across studies.
A meta-analysis by Akinpelu et al. (6) included data from
18 studies and obtained results (OR: 1.91; 95% CI: 1.47–2.49)
similar to our crude analysis. This meta-analysis included
people with type 2 diabetes (26–70 years old) and a disease
duration of 2.9–14.6 years (some studies did not provide this
information). Thus, the ORs reported by Horikawa et al. (9)
and Akinpelu et al. (6) were similar to that obtained in this
study (crude analysis), even though the participant char-
acteristics differed across studies and the average age of the
participants and the mean duration of diabetes were lower in
our study.
Figure 1 - Means of hearing thresholds for ND (n=710) and D (n=191) groups (without exclusion of noise effect) and for ND excluded
noise (n=450) and D excluded noise (n=120); p-values.
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Uchida et al. (16) argued that the association between
diabetes and HL could not be strongly supported because
many confounding variables may affect this association, includ-
ing noise exposure and presbycusis. Indeed, other studies
that investigated the effects of diabetes on hearing function
did not remove confounding factors such as exposure to
noise (22,26,27), gender (22,26,28), age (26), and hyperten-
sion (6,9,16).
Thus, we attempted to control for these possible con-
founding factors in our study and determine whether the
differences observed in the initial analyses (Tables 1 and 2 –
crude analysis) were also present (i.e., D participants had
lower hearing thresholds than ND participants) after models
were adjusted for age, gender, hypertension diagnosis, and
exposure to noise.
Hearing threshold and speech test results were not signi-
ficantly different between the D and ND groups after adjust-
ing for age, gender, and presence of hypertension (Table 3),
and the number of participants with HL was not significantly
higher in the D than ND group at either low- to middle-
range frequencies or high-range frequencies in the adjusted
model (Table 2).
This last analysis suggested that age contributed most to
the worse hearing thresholds of participants with diabetes
observed previously (Tables 1 and 2 – crude model), which
does not support the findings of other studies (9,16,29)
showing a more severe effect of diabetes on hearing in
younger age groups. Nevertheless, we cannot rule out
residual confounding by age, especially in older age groups.
Regarding speech tests, few studies have compared results
between subjects with and without diabetes (12,26). Con-
cerning the results obtained in this study, before the adjust-
ments for sex, age and hypertension, there was a difference
between the D and ND groups in both SRT and SDS.
However, for both groups, the means were within normal
limits. This finding can be explained because the frequencies
that most contribute to the detection and discrimination of
speech signals, which are between 500 and 2,000 Hz, did not
show hearing threshold impairment in either group. Miller
et al. (12) found similar results for speech tests between
groups with and without diabetes and suggested that more
sensitive speech tests (e.g., filtered speech tests) should be
used in order to reveal the more subtle changes that occur
within the auditory pathway.
Lastly, we conducted another comparison (Figure 1), exclud-
ing participants with a history of noise exposure, and found
that mean hearing thresholds were not significantly different
between the D and ND groups after individuals with history of
noise exposure were removed from the analysis. This result
indicates that hearing thresholds were not significantly affected
by noise exposure in our study population. Similar findings
were reported by Horikawa et al. (9).
Some studies have reported a positive association between
the duration of diabetes and HL (25,26). However, the study
populations and methods used in previous studies differ
considerably from those in this study, which may explain the
conflicting results. Sunkum and Pingile (25) included
subjects with type 1 and 2 diabetes (5–55 years old), and
the duration of disease ranged from E1–10 years. Con-
versely, Ozel et al. (26) included only subjects with type 1
diabetes (23–60 years old), but the authors did not report
fasting blood glucose levels; in addition, most participants
were women (465%), and the duration of disease ranged
from E3–13 years.
Other studies reported no association between the duration
of diabetes and progression of HL (6,25). The meta-analysis
by Akinpelu et al. (6) found no significant relationship
between SNHL and the duration of diabetes in a pooled
analysis of the data. The authors observed that only one
study showed a positive association, whereas four failed to
find any significant relationship. Similarly, Agarwal et al. (24)
found no association between the duration of diabetes
and progression of HL in a study that included subjects
with type 1 and 2 diabetes (18–50 years old) and a time from
diagnosis ranging from ‘‘recently diagnosed’’ to 45 years.
The differences in study populations and methods across
studies may explain the controversial findings, and thus the
association between HL and duration of diabetes remains
unclear (22). Cohort studies that examine hearing thresholds
among people with diabetes over time may provide a more
clear understanding of this relationship.
Another issue regarding the effect of diabetes on HL that
may have affected the results of previous studies is that
many studies have relied on self-reporting by participants
(6,9,23), which may result in biased underestimation of
diabetes cases (30). In our study, blood parameters including
fasting serum glucose, HbA1c levels, and 2-h oral glucose
tolerance, which are the main criteria for the diagnosis of
diabetes along with clinical symptoms, were also measured
and further support our findings.
In a review by Hong et al. (30), the authors discussed some
theories about the physiological mechanisms that might
explain HL in diabetes, such as microangiopathy, advanced
glycation end products, and reactive oxygen species, among
others.
Microangiopathy resulting from hyperglycemia may affect
the cochlea, which is highly vascularized (7,12,30). Moreover,
vascular changes to nervous tissue could cause ischemia,
resulting in the loss of nerve fibers and demyelination (7).
Kakarlapudi et al. (22) found that increasing serum cre-
atinine levels correlated with worse hearing in a subject with
diabetes who had SNHL likely as a result of microangio-
pathy in the inner ear. Similarly, Agarwal et al. (24) reported
that subjects with good glycemic control had significantly
better hearing thresholds than those with poor glycemic
control (HbA1c458 mmol/mol). Conversely, Asma et al. (17)
found no significant relationship between HL and glycemic
control.
The lack of an association between diabetes and HL in our
study may be because our study population was relatively
young and most subjects had adequate glycemic control
(78.4% of participants in D group) at ELSA-Brasil baseline.
Thus, we assume that these participants did not have
advanced microangiopathy, and their cochlear tissues were
not directly affected by diabetes due to good control of the
condition. This hypothesis could explain the lack of dif-
ference in hearing thresholds between the D and ND groups
after adjusting for age, gender, and hypertension.
The adequate glycemic control in our study population
may be related to the nature of ELSA-Brasil, as cohort volun-
teers are potentially more health-conscious than the general
population. Thus, this fact should be considered when com-
paring our results to those from other cross-sectional
analyses.
This study found no association between diabetes and
worse hearing thresholds after adjusting for age, gender,
and presence of hypertension. It should be noted that the
diagnosis of diabetes was based on objective measures, and
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we also included confounding variables such as age, gender,
presence of hypertension, noise exposure, and duration of
diabetes, which have not been examined simultaneously in
all studies on the effect of diabetes on SNHL. However, the
mean age of participants and the duration of diabetes were
relatively low in our study population, and glycemic control
was adequate, which may have affected our findings.
Hearing thresholds and speech test results were signifi-
cantly worse in D than in ND participants. However, after
adjusting for age, gender, and the presence of hypertension,
no significant differences were found between the groups. In
addition, hearing thresholds were not affected by noise
exposure in D or ND participants. Together, these findings
revealed no association between the duration of diabetes and
worse hearing thresholds after adjusting for age, gender, and
hypertension.
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